AMBROXOL IN FORMULAZIONE RITARDO NEL TRATTAMENTO A MEDIO TERMINE DELLA BRONCOPNEUMOPATIA CRONICA OSTRUTTIVA

Translated title of the contribution: Sustained release formulation of ambroxol in medium-term treatment of chronic obstructive bronchopneumopathy

C. F. Donner, C. Fracchia, F. Ioli

Research output: Contribution to journalArticle

Abstract

We carried out a comparative study in 50 hospitalized COLD patients in order to evaluate the clinical effectiveness of sustained-release ambroxol against ambroxol. According to a randomized trial 25 patients (mean age 59,2±3,5 years) received sustained-release ambroxol at the dose of 150 mg per day (2 tablets in a single administration) for 8 days and then 75 mg until the end of a 15 day long treatment. The other 25 patients (mean age 63±3,1) received ambroxol at the dose of 90 mg per day (a 30 mg table three times per day) for 8 days and then 60 mg until the 15th day of treatment. At the beginning of the study, on the 1st, 2nd, 3rd, 4th, and then every two days we evaluated the volume and characteristics of sputum, symptoms (cough, wheeziness and difficulty in coughing up) and objective clinical signs. We observed in both groups a progressive reduction of baseline sputum volume (-26 and 30% after 4 days, -41 and 42% after 8 days, -65 and 70% at the end of treatment for sustained release ambroxol and ambroxol, respectively), a reduction in sputum viscosity (3,8→2.4 and 3.4→2, respectively) and an improvement in the clinical state of the patients. The drug appeared to be well tolerated, since we observed no adverse reaction of any importance, either seen by the physicians or shown by laboratory examinations. So we can conclude that both sustained-release ambroxol and ambroxol have a prolonged and favourable effect either in reducing sputum viscosity or in improving the well-being of the patient.

Original languageItalian
Pages (from-to)149-154
Number of pages6
JournalMinerva Pneumologica
Volume24
Issue number2
Publication statusPublished - 1985

Fingerprint

Ambroxol
Sputum
Therapeutics
Viscosity
Cough
Tablets
Physicians

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

AMBROXOL IN FORMULAZIONE RITARDO NEL TRATTAMENTO A MEDIO TERMINE DELLA BRONCOPNEUMOPATIA CRONICA OSTRUTTIVA. / Donner, C. F.; Fracchia, C.; Ioli, F.

In: Minerva Pneumologica, Vol. 24, No. 2, 1985, p. 149-154.

Research output: Contribution to journalArticle

Donner, C. F. ; Fracchia, C. ; Ioli, F. / AMBROXOL IN FORMULAZIONE RITARDO NEL TRATTAMENTO A MEDIO TERMINE DELLA BRONCOPNEUMOPATIA CRONICA OSTRUTTIVA. In: Minerva Pneumologica. 1985 ; Vol. 24, No. 2. pp. 149-154.
@article{7291da7f0af44eeeb35c93704a6069c4,
title = "AMBROXOL IN FORMULAZIONE RITARDO NEL TRATTAMENTO A MEDIO TERMINE DELLA BRONCOPNEUMOPATIA CRONICA OSTRUTTIVA",
abstract = "We carried out a comparative study in 50 hospitalized COLD patients in order to evaluate the clinical effectiveness of sustained-release ambroxol against ambroxol. According to a randomized trial 25 patients (mean age 59,2±3,5 years) received sustained-release ambroxol at the dose of 150 mg per day (2 tablets in a single administration) for 8 days and then 75 mg until the end of a 15 day long treatment. The other 25 patients (mean age 63±3,1) received ambroxol at the dose of 90 mg per day (a 30 mg table three times per day) for 8 days and then 60 mg until the 15th day of treatment. At the beginning of the study, on the 1st, 2nd, 3rd, 4th, and then every two days we evaluated the volume and characteristics of sputum, symptoms (cough, wheeziness and difficulty in coughing up) and objective clinical signs. We observed in both groups a progressive reduction of baseline sputum volume (-26 and 30{\%} after 4 days, -41 and 42{\%} after 8 days, -65 and 70{\%} at the end of treatment for sustained release ambroxol and ambroxol, respectively), a reduction in sputum viscosity (3,8→2.4 and 3.4→2, respectively) and an improvement in the clinical state of the patients. The drug appeared to be well tolerated, since we observed no adverse reaction of any importance, either seen by the physicians or shown by laboratory examinations. So we can conclude that both sustained-release ambroxol and ambroxol have a prolonged and favourable effect either in reducing sputum viscosity or in improving the well-being of the patient.",
author = "Donner, {C. F.} and C. Fracchia and F. Ioli",
year = "1985",
language = "Italian",
volume = "24",
pages = "149--154",
journal = "Minerva Pneumologica",
issn = "0026-4954",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "2",

}

TY - JOUR

T1 - AMBROXOL IN FORMULAZIONE RITARDO NEL TRATTAMENTO A MEDIO TERMINE DELLA BRONCOPNEUMOPATIA CRONICA OSTRUTTIVA

AU - Donner, C. F.

AU - Fracchia, C.

AU - Ioli, F.

PY - 1985

Y1 - 1985

N2 - We carried out a comparative study in 50 hospitalized COLD patients in order to evaluate the clinical effectiveness of sustained-release ambroxol against ambroxol. According to a randomized trial 25 patients (mean age 59,2±3,5 years) received sustained-release ambroxol at the dose of 150 mg per day (2 tablets in a single administration) for 8 days and then 75 mg until the end of a 15 day long treatment. The other 25 patients (mean age 63±3,1) received ambroxol at the dose of 90 mg per day (a 30 mg table three times per day) for 8 days and then 60 mg until the 15th day of treatment. At the beginning of the study, on the 1st, 2nd, 3rd, 4th, and then every two days we evaluated the volume and characteristics of sputum, symptoms (cough, wheeziness and difficulty in coughing up) and objective clinical signs. We observed in both groups a progressive reduction of baseline sputum volume (-26 and 30% after 4 days, -41 and 42% after 8 days, -65 and 70% at the end of treatment for sustained release ambroxol and ambroxol, respectively), a reduction in sputum viscosity (3,8→2.4 and 3.4→2, respectively) and an improvement in the clinical state of the patients. The drug appeared to be well tolerated, since we observed no adverse reaction of any importance, either seen by the physicians or shown by laboratory examinations. So we can conclude that both sustained-release ambroxol and ambroxol have a prolonged and favourable effect either in reducing sputum viscosity or in improving the well-being of the patient.

AB - We carried out a comparative study in 50 hospitalized COLD patients in order to evaluate the clinical effectiveness of sustained-release ambroxol against ambroxol. According to a randomized trial 25 patients (mean age 59,2±3,5 years) received sustained-release ambroxol at the dose of 150 mg per day (2 tablets in a single administration) for 8 days and then 75 mg until the end of a 15 day long treatment. The other 25 patients (mean age 63±3,1) received ambroxol at the dose of 90 mg per day (a 30 mg table three times per day) for 8 days and then 60 mg until the 15th day of treatment. At the beginning of the study, on the 1st, 2nd, 3rd, 4th, and then every two days we evaluated the volume and characteristics of sputum, symptoms (cough, wheeziness and difficulty in coughing up) and objective clinical signs. We observed in both groups a progressive reduction of baseline sputum volume (-26 and 30% after 4 days, -41 and 42% after 8 days, -65 and 70% at the end of treatment for sustained release ambroxol and ambroxol, respectively), a reduction in sputum viscosity (3,8→2.4 and 3.4→2, respectively) and an improvement in the clinical state of the patients. The drug appeared to be well tolerated, since we observed no adverse reaction of any importance, either seen by the physicians or shown by laboratory examinations. So we can conclude that both sustained-release ambroxol and ambroxol have a prolonged and favourable effect either in reducing sputum viscosity or in improving the well-being of the patient.

UR - http://www.scopus.com/inward/record.url?scp=0022362872&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022362872&partnerID=8YFLogxK

M3 - Articolo

VL - 24

SP - 149

EP - 154

JO - Minerva Pneumologica

JF - Minerva Pneumologica

SN - 0026-4954

IS - 2

ER -